Literature DB >> 30036220

Use of a Sentinel Lymph Node Biopsy Algorithm in a South African Population of Patients With Cervical Cancer and High Prevalence of Human Immunodeficiency Virus Infection.

Leon Cornelius Snyman1, Emma P Bryant1, Elize I Wethmar1, Tom de Greve1, Florette Reyneke2, Mike M Sathekge2, Barend G Lindeque1, Nadeem R Abu-Rustum.   

Abstract

OBJECTIVES: Cervical cancer is common in resource-poor settings with high prevalence of tuberculosis, pelvic inflammatory disease, and human immunodeficiency virus (HIV) infection. There are no data regarding the sentinel lymph node (SLN) algorithm in these high-risk cancer populations. Our objectives were to establish the sensitivity, specificity, positive predictive value, and negative predictive value of the SLN algorithm in cervical cancer and to compare the detection rate of indocyanine green (ICG) versus blue dye versus technetium Tc 99m nanocolloid (Tc).
METHODS: This prospective study was conducted at the University of Pretoria. Tc-nanocolloid tracer, ICG dye, and methylene blue (MB) were used to detect SLNs. Pathological ultrastaging was performed on hematoxylin-eosin- negative nodes.
RESULTS: Results of 72 women were analyzed. The mean age was 47.2 years, 5.5% had a history of tuberculosis, 18.1% had pelvic inflammatory disease, and 65.3% were HIV positive. The SLN detection rate was 65.3%. Detection rate of MB was 56.9%; Tc, 69.4%; ICG, 87.5%; and the combination of MB and Tc, 91.7%. Pelvic nodal metastases occurred in 26.4%. The sensitivity, specificity, negative predictive value, and positive predictive value of SLN biopsy were 85.7%, 100%, 100%, and 98.33%, respectively. The false-negative rate was 14.3%, and it was 0% if the algorithm was applied.
CONCLUSIONS: The SLN algorithm is a feasible option for use in cervical cancer women with a high prevalence of HIV infection. The detection rate is generally lower, but in select subgroups of women, it was comparable to that reported elsewhere. This is the first report of the use of SLN biopsy in a substantial group of HIV-infected women.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30036220      PMCID: PMC6639793          DOI: 10.1097/IGC.0000000000001310

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  4 in total

1.  Identification and Biopsy of Sentinel Lymph Node in Early-Stage Cervical Carcinoma: Diagnostic Accuracy and Clinical Utility.

Authors:  Ioanna Koutroumpa; Michail Diakosavvas; Maria Sotiropoulou; Vasilios Pergialiotis; Kyveli Angelou; Michalis Liontos; Dimitrios Haidopoulos; Aristotelis Bamias; Alexandros Rodolakis; Nikolaos Thomakos
Journal:  Cureus       Date:  2022-04-05

2.  Clinical Study of Sentinel Lymph Node Detection to Evaluate Pelvic Lymph Node Metastasis to Determine the Prognosis of Patients with Early Cervical Cancer.

Authors:  Peipei Li; Shuai Feng; Guodong Zhou; Lu Zhang; Xiugui Sheng; Dapeng Li
Journal:  Appl Bionics Biomech       Date:  2022-03-23       Impact factor: 1.781

3.  Sentinel lymph node mapping with indocyanine green in cervical cancer patients undergoing open radical hysterectomy: a single-institution series.

Authors:  Nicolò Bizzarri; Pedone Anchora Luigi; Gabriella Ferrandina; Gian Franco Zannoni; Maria Vittoria Carbone; Camilla Fedele; Elena Teodorico; Valerio Gallotta; Salvatore Gueli Alletti; Vito Chiantera; Anna Fagotti; Giovanni Scambia; Francesco Fanfani
Journal:  J Cancer Res Clin Oncol       Date:  2020-09-30       Impact factor: 4.553

4.  Indocyanine green versus technetium-99m with blue dye for sentinel lymph node detection in early-stage cervical cancer: A systematic review and meta-analysis.

Authors:  Ilse G T Baeten; Jacob P Hoogendam; Bernadette Jeremiasse; Arthur J A T Braat; Wouter B Veldhuis; Geertruida N Jonges; Ina M Jürgenliemk-Schulz; Carla H van Gils; Ronald P Zweemer; Cornelis G Gerestein
Journal:  Cancer Rep (Hoboken)       Date:  2021-05-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.